Conbercept Ophthalmic Injection: Clinical Trials

4 trials of Conbercept Ophthalmic Injection, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 not yet recruiting, 1 unknown. 2 Phase 3, 1 Not applicable, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 32Completed 2
Not applicable1Not yet recruiting 1
Phase 21Unknown 1

Follow Conbercept Ophthalmic Injection: new trials by email Literature Review of Conbercept Ophthalmic Injection trials Research Report on Conbercept Ophthalmic Injection

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study on the Combination of Tongluo Huayu Formula in Treating RVO of Phlegm-Stasis Intertwinement Type: Based on the Mechanism of Systemic Metabolic Regulation Mediated by Gut Microbiota
Conbercept Ophthalmic Injection, Tongluo Huayu Formula, Laser Photocoagulation - Retinal Vein Occlusion
Not applicableNot yet recruitingFirst Affiliated Hospital of Zhejiang University802026-06-012026-07-22
A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma
Conbercept ophthalmic injection - Retinoblastoma
Phase 2UnknownChengdu Kanghong Biotech Co., Ltd.922021-07-052021-08-04
Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion
Conbercept Ophthalmic Injection, sham injection - Macular Edema, Central Retinal Vein Occlusion
Phase 3CompletedChengdu Kanghong Biotech Co., Ltd.2422016-05-242022-07-13
Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion
Conbercept ophthalmic injection, sham/Conbercept ophthalmic injection - Branch Retinal Vein Occlusion, Macular Edema
Phase 3CompletedChengdu Kanghong Biotech Co., Ltd.2552016-04-132022-07-15

Conditions studied

Retinal Vein Occlusion (3)  ·  Macular Edema (2)  ·  Retinoblastoma (1)

Sponsors

Chengdu Kanghong Biotech Co., Ltd. (3)  ·  First Affiliated Hospital of Zhejiang University (1)

Countries

China (4)

Top investigators

Hongguang Cui (1)

Results publications

PMID 32633861, PMID 42778337